Implementation of contemporary chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma: a population-based analysis

  • Anouk E. J. Latenstein (University of Amsterdam) (Creator)
  • Tara Mackaij (Creator)
  • Geert-Jan Creemers (Contributor)
  • Casper H. J. van Eijck (Contributor)
  • Jan Willem B. de Groot (Contributor)
  • Nadia Haj Mohammad (University Medical Centre Utrecht) (Contributor)
  • Marjolein Y. V. Homs (Creator)
  • Hanneke van Laarhoven (Contributor)
  • I. Quintus Molenaar (Contributor)
  • Bert-Jan ten Tije (Contributor)
  • Judith de Vos-Geelen (Contributor)
  • Marc Besselink (Creator)
  • Lydia G. M. van der Geest (Department of Research and Development) (Contributor)
  • Johanna W. Wilmink (Creator)
  • Hanneke W.M. Van Laarhoven (Creator)
  • Marc G. Besselink (Creator)
  • Johanna W. Wilmink (Creator)



Background: Positive results of randomized trials led to the introduction of FOLFIRINOX in 2012 and gemcitabine with nab-paclitaxel in 2015 for patients with metastatic pancreatic ductal adenocarcinoma. It is unknown to which extent these new chemothera...
Date made available2020
PublisherTaylor & Francis

Cite this